Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
3.595
-0.065 (-1.78%)
Oct 16, 2025, 9:30 AM EDT - Market open
Pyxis Oncology Revenue
Pyxis Oncology had revenue of $2.82M in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $2.82M, down -82.53% year-over-year. In the year 2024, Pyxis Oncology had annual revenue of $16.15M.
Revenue (ttm)
$2.82M
Revenue Growth
-82.53%
P/S Ratio
79.49
Revenue / Employee
$64,091
Employees
44
Market Cap
222.96M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 16.15M | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PYXS News
- 2 days ago - Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings - GlobeNewsWire
- 7 days ago - Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - GlobeNewsWire
- 15 days ago - Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Pyxis Oncology to Participate in September Investor and Industry Conferences - GlobeNewsWire
- 2 months ago - Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Pyxis Oncology to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 6 months ago - Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC - GlobeNewsWire